About miRdetect
miRdetect is a biotechnology company founded in 2016, with the aim to revolutionise cancer diagnostics. The focus is on development, production and distribution of in-vitro diagnostics based on molecular diagnostic methods. The first product, based on the quantification of microRNA, is a blood test for the detection of testicular cancer. The high sensitivity and accuracy of the test improves the diagnosis and therapy of patients significantly and reduces the costs for the health care system. miRdetect has developed a patented platform technology, which allows the exact and reliable quantification of small amounts of genetic material in body fluids. This robust method represents the basis for the development of additional diagnostic tests.
Press releases
Press
miRdetect Receives Seed Financing – Consortium Invests Seven-Digit Amount in Serum Marker for Testicular Cancer Detection
High-Tech Gründerfonds (HTGF), BAB Beteiligungs- und Managementgesellschaft Bremen mbH (BBM) and a private investor invest in Bremen start-up miRdetect
miRdetect develops an innovative and accurate test method for the detection of testicular cancer
Together with BBM and a private investor, High-Tech Gründerfonds (HTGF) is investing a seven-figure sum in the start-up company miRdetect located in Bremen, and founded in 2016. The company founders Meike Spiekermann and Dr. Nina Winter were
Info & Contact
Address
Fahrenheitstraße 1
28359 Bremen
28359 Bremen
In portfolio
14. Dec 2018
Sector
Dr. Angelika Vlachou
Partner